

ESPI current report

Number: 40/2025
Date of preparation September 25, 2025
Company Genomtec SA based in Wrocław

Title	Receipt of a decision from the European Patent Office to grant a European patent.
--------------	--

Legal basis: Article 17 paragraph 1 of MAR - confidential information.

Content of the Report: The Management Board of Genomtec S.A. with its registered office in Wrocław (hereinafter referred to as the "Issuer", "Company") hereby announces that on September 25, 2025, it received information about the granting of a European patent for the invention entitled: "Set of primers, composition of reagents and method of detecting atypical bacteria" granted by the European Patent Office.

The development of a primer set is a key element of the LAMP-based diagnostic method used by the Issuer. The primers initiate the amplification reaction by recognizing a specific fragment of the pathogen's genome. The patent application described here mitigates the risk of competitors using the same primer set.

The period of protection for the invention in question was granted by the European Patent Office subject to the condition of timely payment of official fees for subsequent years of protection.

The Issuer announces that this is the sixteenth patent granted to the Company. The Issuer has over thirty patent applications pending worldwide.

In the opinion of the Management Board, a high level of intellectual property protection will also provide the Company with an appropriate negotiating position before signing commercial agreements with selected partners regarding the implementation of the commercialization strategy.

Patent proceedings are aimed at securing key interests and are part of the Issuer's development strategy, which includes building a portfolio of intellectual property rights.

Signatures of persons representing the Company:

Michał Wachowski - Member of the Management Board